General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises insitro in its US$143 Million Series B Financing

May 26, 2020
The financing will help expand the company's machine-learning-enabled drug discovery capabilities and advance therapeutic programs.

insitro, a machine-learning driven drug discovery and development company, has announced that it has raised US$143 million in an oversubscribed Series B financing. The financing was led by Andreessen Horowitz, with participation from new investors Canada Pension Plan Investment Board (CPP Investments) and funds and accounts advised by T. Rowe Price Associates, Inc. as well as funds managed by BlackRock, Casdin Capital, HOF Capital, WuXi AppTec’s Corporate Venture Fund, and other undisclosed investors. Current investors ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, and Alexandria Venture Investments also participated in the financing.

Latham & Watkins LLP represents insitro in the financing with a Bay Area-based team led by partners Brian Cuneo and Miles Jennings, with associates Meredith Peake and Natalie Robertson.


    Related Capabilities